Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
WMJ : Official Publication of the State Medical Society of Wisconsin|July 23, 2016
A Survey of Baseline Tobacco Cessation Clinical Practices and Receptivity to Academic DetailingRobert Adsit, Kari Wisinski, Ryan Mattison, et al.
Leukemia & Lymphoma|January 19, 2008
Phase II study of doxercalciferol for the treatment of myelodysplastic syndromeAdam Petrich, Brad Kahl, Howard Bailey, et al.
International Journal of Gastrointestinal Cancer|June 10, 2003
Phase II trial of perillyl alcohol in patients with metastatic colorectal cancerSherry Morgan Meadows, Daniel Mulkerin, Jordan Berlin, et al.
WMJ : Official Publication of the State Medical Society of Wisconsin|May 13, 2011
The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) studyDennis J Baumgardner, Jonathan L Temte, Erin Gutowski, et al.
Investigational New Drugs|January 13, 2011
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation designAmye Tevaarwerk, George Wilding, Jens Eickhoff, et al.
Cancer|February 3, 2011
A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)Scott Okuno, Howard Bailey, Michelle R Mahoney, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2008
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumorsWilliam Schelman, Sherry Morgan-Meadows, Howard Bailey, et al.
WMJ : Official Publication of the State Medical Society of Wisconsin|February 6, 2010
The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research groupHoward Bailey, William Agger, Dennis Baumgardner, et al.
Oncology|August 25, 2005
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinomaSherry Morgan-Meadows, Daniel Mulkerin, Jordan D Berlin, et al.
The Prostate|January 22, 2013
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pinJason Gee, Howard Bailey, Kyungmann Kim, et al.
Pageof 2